All News
Paradoxical Psoriasis in Kids Taking TNF Inhibitors
A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.
Read Article
High BMI Increases Arthritis Risk
Obesity carries many risks, now a new study in Arthritis & Rheumatology shows that higher body mass index (BMI) increases the risk for several rheumatic diseases, especially in women for both gout and psoriatic arthropathy.
Read Article
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Adolescents (>12 yrs) With Severe Alopecia Areata (based on ALLEGRO trial, pub in Lancet) https://t.co/VmjhQOnZyS https://t.co/VmjhQOnZyS https://t.co/oUZfckt6DX
Dr. John Cush RheumNow ( View Tweet)
Why Patients Don't Take Medicines
This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost.
https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi
Links:
Dr. John Cush RheumNow ( View Tweet)
c-Fos regulates chondrocyte proliferation and differentiation, and cFOS-positive chondrocytes were increased in human and murine OA cartilage. New research (humans an mice) suggests it plays a role in protecting cartilage and could be a therpeutic target https://t.co/B0tmo0AbQe https://t.co/KPrOm3Spfa
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Colchicine for CV Prevention
The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
https://t.co/MEqASrWWMb https://t.co/TmoLEvlPXI
Links:
Dr. John Cush RheumNow ( View Tweet)
Medicare and Commercial claims analysis shows
1 #RA pts at risk for H Zoster
2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ
3 Higher total costsalso higher in month after HZ
https://t.co/iKmvYDqj87 https://t.co/BeZCmMJse7
Links:
Dr. John Cush RheumNow ( View Tweet)
Indian study of 943 AIRD patients (43% RA) starting biologics or JAKi, had TB screening with IGRA assay. 125 pts were IGRA pos. and had LTBI; 124/125 received anti-TB prophylaxis. IGRA Accuracy in predicting absence of TB reactivation = 99.6% https://t.co/KI9vGWpS59 https://t.co/Ne33P51koD
Links:
Dr. John Cush RheumNow ( View Tweet)
What is Colchicine Worth?
This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
https://t.co/VAeP4lPKL6 https://t.co/QUPRqxTz5z
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/KNaFynAlXM https://t.co/okO0fLqM54
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/hAj3UZjbHJ https://t.co/eQHjEgelRM
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
https://t.co/tZW3vNCl7T https://t.co/8IB3q3xNY6
Links:
Dr. John Cush RheumNow ( View Tweet)
Chronic Pain Management tools
1 Medication
2 Physical Therapy
3 Cognitive-Behavioral Therapy
4 Mindfulness Meditation
5 Acupuncture
6 Massage
7 Heat/Cold
8 TENS
9 Yoga/Tai Chi
10 Support groups https://t.co/hb6ACoS6Xn https://t.co/AZRM873J6Z
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/0U47rSH7KB https://t.co/SNy8Egw59z
Links:
Dr. John Cush RheumNow ( View Tweet)
Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome?
https://t.co/5GNUZolPsz https://t.co/bIFKPjWBM0
Links:
Dr. John Cush RheumNow ( View Tweet)
Ultrasonography May Improve OA Pain Prediction
Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy.
https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Lupus Highlights
https://t.co/CGybJRjDDK https://t.co/2kkB1hX2J5
Links:
Dr. John Cush RheumNow ( View Tweet)
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
The use of methotrextate with either bDMARDs, tsDMARDs or bsDMARDs was not shown to be cost effective, even though reduced disease activity and improved patient quality of life.
Read more--https://t.co/4nBp0ML8Kl https://t.co/5YXCotHlYK
Links:
Dr. John Cush RheumNow ( View Tweet)
Cancer Risk From RA, Not the Drugs
A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk.
https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z
Links:
Dr. John Cush RheumNow ( View Tweet)